Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivosidenib in CCUS with IDH1 mutations
NCT05030441Phase 2Active, not recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Apr 2022
- Primary completion
- Jan 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ivosidenib in clonal cytopenia of undetermined significance (CCUS), sponsored by Washington University School of Medicine. Started Apr 2022; status: active, not recruiting.
02
Drugs
ivosidenib
03
Conditions
clonal cytopenia of undetermined significance (CCUS)
Beyond the preview
Go deeper on NCT05030441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05030441.